SCHEMBL22159235

SCHEMBL22159235

CC(N[S@@+]([O-])C(C)(C)C)c1ccc(-c2ccc(Cl)cc2)cn1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 5/20 0.33
CYP3A4 P08684 2/20 0.33
CYP17A1 P05093 1/20 0.33
NPC1 O15118 3/20 0.33
RAB9A P51151 3/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
MAPT P10636 3/20 0.33
PRKD3 O94806 1/20 0.33
PRKCG P05129 1/20 0.33
PRKCB P05771 1/20 0.33
BRAF P15056 1/20 0.33
PRKCA P17252 1/20 0.33
PRKCH P24723 1/20 0.33
PRKCI P41743 1/20 0.33
PRKCE Q02156 1/20 0.33
PRKCQ Q04759 1/20 0.33
PRKCZ Q05513 1/20 0.33
PRKCD Q05655 1/20 0.33
PRKD1 Q15139 1/20 0.33
LTA4H P09960 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22159233 1.00 AKT1 (0.33) AKT1CYP3A4CYP17A1NPC1RAB9A
SCHEMBL22159238 1.00 AKT1 (0.33) AKT1CYP3A4CYP17A1NPC1RAB9A
SCHEMBL20758632 0.89 B3GNT2 (0.36) L3MBTL1
SCHEMBL20758639 0.89 B3GNT2 (0.36) L3MBTL1
SCHEMBL22158937 0.86 HDAC6 (0.38) CYP3A4CYP17A1TNF
SCHEMBL22158936 0.86 HDAC6 (0.38) CYP3A4CYP17A1TNF
SCHEMBL22158938 0.86 HDAC6 (0.38) CYP3A4CYP17A1TNF
SCHEMBL12802218 0.85 GRIA2 (0.33) LGMN
SCHEMBL13062791 0.85 GRIA2 (0.33) LGMN
SCHEMBL22159364 0.84 KIF11 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020141439-A1 HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) 2020-07-09 WO disclosed
US-20200206233-A1 HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) 2020-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200206233-A1 HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS IDH1, IDH2, IDH3A AKT1 1016/4885CYP3A4 1010/4885CYP17A1 438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.